Edap Tms (NASDAQ:EDAP) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Edap Tms (NASDAQ:EDAP) posted its quarterly earnings results on Wednesday. The medical equipment provider reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10), FiscalAI reports. Edap Tms had a negative return on equity of 61.60% and a negative net margin of 30.95%.The company had revenue of $22.22 million for the quarter, compared to analysts’ expectations of $21.28 million.

Edap Tms Stock Up 4.8%

NASDAQ:EDAP opened at $3.91 on Wednesday. Edap Tms has a 52 week low of $1.21 and a 52 week high of $5.05. The firm has a market capitalization of $146.19 million, a PE ratio of -6.86 and a beta of -0.19. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average of $4.23 and a 200-day moving average of $3.14.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Edap Tms stock. Rock Springs Capital Management LP lifted its holdings in shares of Edap Tms S.A. (NASDAQ:EDAP) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,286,500 shares of the medical equipment provider’s stock after buying an additional 16,500 shares during the period. Rock Springs Capital Management LP owned approximately 3.44% of Edap Tms worth $4,233,000 at the end of the most recent reporting period. 62.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Edap Tms in a report on Monday, December 29th. Wall Street Zen upgraded shares of Edap Tms to a “hold” rating in a report on Saturday, February 7th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Edap Tms has an average rating of “Hold” and an average price target of $8.50.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.